{"id":"amiodarone-pill","safety":{"commonSideEffects":[{"rate":"1-17%","effect":"Pulmonary toxicity (pneumonitis, fibrosis)"},{"rate":"4-24%","effect":"Thyroid dysfunction (hypo- or hyperthyroidism)"},{"rate":"1-3%","effect":"Hepatotoxicity"},{"rate":"up to 100%","effect":"Corneal microdeposits"},{"rate":"10-25%","effect":"Photosensitivity"},{"rate":"3-5%","effect":"Bradycardia"},{"rate":"null","effect":"QT prolongation"},{"rate":"<1%","effect":"Torsades de pointes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amiodarone is a Class III antiarrhythmic agent that primarily prolongs the action potential duration and refractory period by blocking potassium channels. It also has Class I, II, and IV properties, blocking sodium, beta-adrenergic, and calcium channels respectively. This multi-channel blockade makes it effective for suppressing both atrial and ventricular arrhythmias.","oneSentence":"Amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to slow electrical conduction and suppress abnormal heart rhythms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:10.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation (maintenance of sinus rhythm and rate control)"},{"name":"Ventricular tachycardia and ventricular fibrillation"},{"name":"Supraventricular tachycardia refractory to other agents"}]},"trialDetails":[{"nctId":"NCT04594746","phase":"PHASE4","title":"Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2022-02-03","conditions":"Atrial Fibrillation","enrollment":3},{"nctId":"NCT06657404","phase":"NA","title":"The Modified \"Pills-in-the-Pocket\" Strategy","status":"RECRUITING","sponsor":"Yumei Xue","startDate":"2024-10-23","conditions":"Atrial Fibrillation (AF)","enrollment":328},{"nctId":"NCT04092621","phase":"PHASE4","title":"Rapid Atrial Fibrillation Treatment Strategy","status":"UNKNOWN","sponsor":"Our Lady of the Lake Hospital","startDate":"2019-09-16","conditions":"New Onset Atrial Fibrillation, Sepsis, Respiratory Failure","enrollment":40},{"nctId":"NCT01558830","phase":"PHASE4","title":"Safety of Amiodarone and Ranolazine Together in Patients With Angina","status":"UNKNOWN","sponsor":"Cardiovascular Consultants of Nevada","startDate":"2012-01","conditions":"Chronic Stable Angina, Coronary Artery Disease, Atrial Fibrillation","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cordarone"],"phase":"marketed","status":"active","brandName":"Amiodarone Pill","genericName":"Amiodarone Pill","companyName":"Our Lady of the Lake Hospital","companyId":"our-lady-of-the-lake-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to slow electrical conduction and suppress abnormal heart rhythms. Used for Atrial fibrillation (maintenance of sinus rhythm and rate control), Ventricular tachycardia and ventricular fibrillation, Supraventricular tachycardia refractory to other agents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}